JP2019507764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507764A5 JP2019507764A5 JP2018545847A JP2018545847A JP2019507764A5 JP 2019507764 A5 JP2019507764 A5 JP 2019507764A5 JP 2018545847 A JP2018545847 A JP 2018545847A JP 2018545847 A JP2018545847 A JP 2018545847A JP 2019507764 A5 JP2019507764 A5 JP 2019507764A5
- Authority
- JP
- Japan
- Prior art keywords
- sorafenib
- troxacitabine
- cancer
- drug
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 17
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 16
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 16
- 229960003787 sorafenib Drugs 0.000 claims description 16
- 229940002612 prodrug Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 15
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 claims description 15
- 229950010147 troxacitabine Drugs 0.000 claims description 15
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- -1 X is H Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229960004836 regorafenib Drugs 0.000 claims description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 11
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 150000008298 phosphoramidates Chemical class 0.000 claims 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650274 | 2016-03-02 | ||
| SE1650274-2 | 2016-03-02 | ||
| SE1651204 | 2016-09-08 | ||
| SE1651204-8 | 2016-09-08 | ||
| PCT/SE2017/050186 WO2017151044A1 (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507764A JP2019507764A (ja) | 2019-03-22 |
| JP2019507764A5 true JP2019507764A5 (enExample) | 2020-04-09 |
| JP6968080B2 JP6968080B2 (ja) | 2021-11-17 |
Family
ID=59744330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545847A Active JP6968080B2 (ja) | 2016-03-02 | 2017-02-28 | ソラフェニブ又はレゴラフェニブとトロキサシタビンのホスホロアミデートプロドラッグを用いた併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10456413B2 (enExample) |
| EP (1) | EP3423061B1 (enExample) |
| JP (1) | JP6968080B2 (enExample) |
| KR (1) | KR102703122B1 (enExample) |
| CN (2) | CN111956646B (enExample) |
| AU (2) | AU2017227516B2 (enExample) |
| CA (1) | CA3014769C (enExample) |
| ES (1) | ES2987989T3 (enExample) |
| HR (1) | HRP20241508T1 (enExample) |
| HU (1) | HUE068940T2 (enExample) |
| MY (1) | MY198140A (enExample) |
| PL (1) | PL3423061T3 (enExample) |
| RS (1) | RS66090B1 (enExample) |
| RU (1) | RU2018134336A (enExample) |
| SG (1) | SG11201806855WA (enExample) |
| WO (1) | WO2017151044A1 (enExample) |
| ZA (1) | ZA201805445B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201806855WA (en) | 2016-03-02 | 2018-09-27 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| JP2021512875A (ja) * | 2018-02-02 | 2021-05-20 | カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 細胞免疫療法の組み合わせ |
| JP7337539B2 (ja) | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| HUE065972T2 (hu) * | 2019-02-18 | 2024-06-28 | Medivir Ab | Gyógyszerkombináció a májrák kezelésére szolgáló eljárásban történõ alkalmazásra |
| WO2021211039A1 (en) * | 2020-04-15 | 2021-10-21 | Medivir Ab | Miv-818/lenvatinib combination therapy for liver cancer |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
| IT202000022636A1 (it) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
| TW202444368A (zh) * | 2023-03-30 | 2024-11-16 | 瑞典商米迪維艾克提伯拉公司 | 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CN100376570C (zh) * | 2000-10-13 | 2008-03-26 | 希拉生物化学股份有限公司 | 改善胞间传输的二氧戊环类似物 |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| CA2645633A1 (en) * | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| CN102190616B (zh) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| EP2836216B1 (en) | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN103570613B (zh) | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | 氘代ω-二苯基脲或其盐的多晶型物 |
| EP2879677B1 (en) | 2012-07-28 | 2017-06-14 | Calitor Sciences, LLC | Substituted pyrazolone compounds and methods of use |
| US9872919B2 (en) * | 2012-09-19 | 2018-01-23 | The Research Foundation For The State University Of New York | Prodrugs for selective anticancer therapy |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| JP2017504572A (ja) * | 2013-11-27 | 2017-02-09 | アイデニクス・ファーマシューティカルズ・エルエルシー | 肝臓癌治療のためのヌクレオチド類 |
| EP3572410B1 (en) * | 2014-08-25 | 2022-07-20 | Medivir Aktiebolag | Dioxolane analogues of uridine for the treatment of cancer |
| SG11201806855WA (en) | 2016-03-02 | 2018-09-27 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
-
2017
- 2017-02-28 SG SG11201806855WA patent/SG11201806855WA/en unknown
- 2017-02-28 CN CN202010727607.5A patent/CN111956646B/zh active Active
- 2017-02-28 HU HUE17760400A patent/HUE068940T2/hu unknown
- 2017-02-28 ES ES17760400T patent/ES2987989T3/es active Active
- 2017-02-28 CA CA3014769A patent/CA3014769C/en active Active
- 2017-02-28 WO PCT/SE2017/050186 patent/WO2017151044A1/en not_active Ceased
- 2017-02-28 RS RS20241192A patent/RS66090B1/sr unknown
- 2017-02-28 AU AU2017227516A patent/AU2017227516B2/en active Active
- 2017-02-28 PL PL17760400.6T patent/PL3423061T3/pl unknown
- 2017-02-28 CN CN201780014430.0A patent/CN109069509B/zh active Active
- 2017-02-28 US US16/081,383 patent/US10456413B2/en active Active
- 2017-02-28 MY MYPI2018703064A patent/MY198140A/en unknown
- 2017-02-28 RU RU2018134336A patent/RU2018134336A/ru not_active Application Discontinuation
- 2017-02-28 HR HRP20241508TT patent/HRP20241508T1/hr unknown
- 2017-02-28 EP EP17760400.6A patent/EP3423061B1/en active Active
- 2017-02-28 JP JP2018545847A patent/JP6968080B2/ja active Active
- 2017-02-28 KR KR1020187028361A patent/KR102703122B1/ko active Active
-
2018
- 2018-08-15 ZA ZA2018/05445A patent/ZA201805445B/en unknown
-
2019
- 2019-08-30 US US16/557,511 patent/US10960017B2/en active Active
-
2022
- 2022-06-01 AU AU2022203761A patent/AU2022203761B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018134336A (ru) | Комбинированная терапия сорафенибом или регорафенибом и фосфорамидатным пролекарством троксацитабина | |
| JP2013544846A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| JP2012506870A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2014500295A5 (enExample) | ||
| JP2016502981A5 (enExample) | ||
| JP2016006096A5 (enExample) | ||
| JP2015523397A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| JP2016516773A5 (enExample) | ||
| JP2017505785A5 (enExample) | ||
| JP2016531885A5 (enExample) | ||
| JP2019518034A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2017506640A5 (enExample) | ||
| JP2019534893A5 (enExample) |